Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07633171 · ClinicalTrials.gov registry record

Multimodal Glucose Prediction in Type 2 Diabetes

A clinical trial, sponsored by Johns Hopkins University.

Not yet
Registry status
36
Enrollment target

NCT07633171: Clinical Trial study, sponsored by Johns Hopkins University.

NCT07633171 is a clinical trial that has not yet begun recruiting, run by Johns Hopkins University. The registered enrollment target is 36 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist → Add completion date to calendar (.ics) →

The verdict

NCT07633171 has not yet begun recruiting, sponsored by Johns Hopkins University.

NOT YET RECRUITING
Registry status
36 participants
Enrollment target

Study Summary

The primary objective of this research, funded by Samsung Strategic Alliance for Research and Technology, is to develop multi-modal foundation models that integrate Continuous Glucose Monitoring (CGM) data with patient behavior data (food intake, medication, and physical activity) to improve real-time glucose prediction and personalized diabetes management for patients with Type 2 diabetes (T2D), delivered via mobile apps and digital health tools.

Primary Outcome

Model performance will be evaluated using root mean square error to compare predicted continuous glucose monitor glucose values with observed continuous glucose monitor glucose values. Model performance using continuous glucose monitor data alone will be compared with model performance using continuous glucose monitor data plus behavioral measures, including physical activity and diet logs.

Interventions

  • DEVICE Digital Health Data Collection System

Trial Details

FieldValue
Enrollment Target 36 participants
Start Date 2026-06-15
Est. Completion 2027-02-26
Johns Hopkins University

1,448 total trials

What is known before NCT07633171 opens enrollment

NCT07633171 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 36 participants, a relatively small participant target.

The record links to 0 conditions, and to 1 intervention - of which Digital Health Data Collection System is the first listed.

NCT07633171 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT07633171 about?

NCT07633171 is a clinical study titled "Multimodal Glucose Prediction in Type 2 Diabetes". The primary objective of this research, funded by Samsung Strategic Alliance for Research and Technology, is to develop multi-modal foundation models that integrate Continuous Glucose Monitoring (CGM) data with patient behavior data (food intake, medication, and physical activity) to improve real-ti...

What is the current status of trial NCT07633171?

This trial is currently not yet recruiting. The enrollment target is 36 participants. The study started on 2026-06-15. Estimated completion is 2027-02-26.

What interventions are being tested in trial NCT07633171?

The interventions under investigation include: Digital Health Data Collection System (DEVICE).

Who is sponsoring clinical trial NCT07633171?

This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00929006 · 36 participants · Early Phase 1

    Acute Progesterone Suppression of Wake vs. Sleep Luteinizing Hormone Pulse Frequency in Pubertal Girls With and Without Hyperandrogenism

  • NCT01891318 · 36 participants · Phase 1

    Neoadjuvant Radiosurgery for Resectable Brain Metastases: Phase I/II Study

  • NCT02291848 · 36 participants · Phase 1

    Tumor-Associated Antigen-Specific Cytotoxic T-Lymphocytes for Multiple Myeloma

  • NCT02366819 · 36 participants · Phase 4

    Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT07633171, the US trial registry maintained by the National Library of Medicine. NCT07633171 (small enrollment · none site footprint · not yet recruiting) retrieved and formatted by PlainTrial, see methodology.